The FDA approved Cobenfy, a new drug for schizophrenia that targets cholinergic receptors, unlike previous treatments that targeted dopamine receptors. It promises to revolutionize schizophrenia treatment and has shown significant symptom improvement in trials. The drug is manufactured by Bristol Myers Squibb and has a novel approach to treating the disorder. The approval is seen as a landmark for the community, with potential to change the treatment paradigm. Common side effects include weight loss, nausea, and dizziness. Individuals with certain health conditions are advised not to take the medication. The drug offers a new alternative for those with schizophrenia and may improve their quality of life.
Source link
New Drug Offers Novel Treatment Mechanism For Schizophrenia
